0 CHECKOUT

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

  • ID: 3500433
  • October 2015
  • 285 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Immuron Limited
  • Novartis AG
  • Shire Plc
  • MORE

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

Summary

The report ‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015’, provides an overview of the Non-Alcoholic Steatohepatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Immuron Limited
  • Novartis AG
  • Shire Plc
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Non-Alcoholic Steatohepatitis Overview

Therapeutics Development

Pipeline Products for Non-Alcoholic Steatohepatitis - Overview

Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis

Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies

Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes

Non-Alcoholic Steatohepatitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Non-Alcoholic Steatohepatitis - Products under Development by Companies

Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes

Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development

AlbireoPharma

Aquinox Pharmaceuticals Inc.

Ardelyx, Inc.

Arisaph Pharmaceuticals, Inc.

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cardax Pharmaceuticals, Inc.

Cerenis Therapeutics Holding SA

Conatus Pharmaceuticals Inc.

Connexios Life Sciences Pvt. Ltd.

Daiichi Sankyo Company, Limited

Dr. Falk Pharma GmbH

DURECT Corporation

Dynavax Technologies Corporation

Enanta Pharmaceuticals, Inc.

Exicure, Inc.

Galectin Therapeutics, Inc.

Galmed International Ltd.

Genfit SA

GenKyoTex S.A.

Gilead Sciences, Inc.

iCo Therapeutics Inc.

Immuron Limited

Intercept Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Jenrin Discovery, Inc.

Kissei Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Mochida Pharmaceutical Co., Ltd.

NGM Biopharmaceuticals, Inc.

Nimbus Therapeutics, LLC

Nippon Chemiphar Co., Ltd.

Novartis AG

Novo Nordisk A/S

ProMetic Life Sciences Inc.

Protalix BioTherapeutics, Inc.

Regulus Therapeutics Inc.

RuiYi Inc.

Shire Plc

Stelic Institute & Co.

Therapix Biosciences Ltd

Tobira Therapeutics, Inc.

Vascular Biogenics Ltd.

Verva Pharmaceuticals Limited

Viking Therapeutics, Inc.

Virobay Inc.

Zafgen Inc.

Zydus Cadila Healthcare Limited

Non-Alcoholic Steatohepatitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(leucine + metformin + sildenafil) - Drug Profile

A-4250 - Drug Profile

AM-0010 - Drug Profile

AQX-1125 - Drug Profile

Aramchol - Drug Profile

ARI-3037MO - Drug Profile

bertilimumab - Drug Profile

BMS-986036 - Drug Profile

BOT-191 - Drug Profile

CDX-085 - Drug Profile

cenicriviroc mesylate - Drug Profile

CER-209 - Drug Profile

CNX-014 - Drug Profile

CNX-023 - Drug Profile

CNX-024 - Drug Profile

CNX-025 - Drug Profile

DUR-928 - Drug Profile

DV-1179 - Drug Profile

elafibranor - Drug Profile

emricasan - Drug Profile

etanercept biosimilar - Drug Profile

GKT-831 - Drug Profile

GR-MD-02 - Drug Profile

icosapent ethyl - Drug Profile

IMM-124E - Drug Profile

ISIS-DGAT2Rx - Drug Profile

JD-5037 - Drug Profile

JKB-119 - Drug Profile

JKB-121 - Drug Profile

liraglutide (recombinant) - Drug Profile

LJN-452 - Drug Profile

MAT-8800 - Drug Profile

methazolamide - Drug Profile

MGL-3196 - Drug Profile

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile

NC-101 - Drug Profile

NC-2400 - Drug Profile

ND-630 - Drug Profile

ND-654 - Drug Profile

NDI-010976 - Drug Profile

NGM-282 - Drug Profile

norursodeoxycholic acid - Drug Profile

NP-201 - Drug Profile

obeticholic acid - Drug Profile

Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile

PBI-4050 - Drug Profile

pentamidine isethionate - Drug Profile

Px-102 - Drug Profile

Px-103 - Drug Profile

PXS-4728A - Drug Profile

PZ-235 - Drug Profile

RDX-009 - Drug Profile

remogliflozin etabonate - Drug Profile

RG-125 - Drug Profile

RYI-018 - Drug Profile

saroglitazar - Drug Profile

SDP-051 - Drug Profile

selonsertib - Drug Profile

simtuzumab - Drug Profile

Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile

Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile

solithromycin - Drug Profile

SR-9238 - Drug Profile

STNM-09 - Drug Profile

TGFTX-3 Program - Drug Profile

tipelukast - Drug Profile

TRX-318 - Drug Profile

VB-201 - Drug Profile

VBY-376 - Drug Profile

VK-0214 - Drug Profile

VK-2809 - Drug Profile

volixibat potassium - Drug Profile

VVP-100-X - Drug Profile

ZGN-839 - Drug Profile

Non-Alcoholic Steatohepatitis - Recent Pipeline Updates

Non-Alcoholic Steatohepatitis - Dormant Projects

Non-Alcoholic Steatohepatitis - Discontinued Products

Non-Alcoholic Steatohepatitis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2015

Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Development by Companies, H2 2015 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Ardelyx, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Galmed International Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Mochida Pharmaceutical Co., Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Regulus Therapeutics Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by RuiYi Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2015

Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H2 2015

Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2015

Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2015

Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2015

Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AlbireoPharma
Aquinox Pharmaceuticals Inc.
Ardelyx, Inc.
Arisaph Pharmaceuticals, Inc.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cardax Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Connexios Life Sciences Pvt. Ltd.
Daiichi Sankyo Company, Limited
Dr. Falk Pharma GmbH
DURECT Corporation
Dynavax Technologies Corporation
Enanta Pharmaceuticals, Inc.
Exicure, Inc.
Galectin Therapeutics, Inc.
Galmed International Ltd.
Genfit SA
GenKyoTex S.A.
Gilead Sciences, Inc.
iCo Therapeutics Inc.
Immuron Limited
Intercept Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Mochida Pharmaceutical Co., Ltd.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Novartis AG
Novo Nordisk A/S
ProMetic Life Sciences Inc.
Protalix BioTherapeutics, Inc.
Regulus Therapeutics Inc.
RuiYi Inc.
Shire Plc
Stelic Institute & Co.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Vascular Biogenics Ltd.
Verva Pharmaceuticals Limited
Viking Therapeutics, Inc.
Virobay Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Abbott Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Actavis
  • Genfit